PANAJI: The Food and Drug Administration (FDA), Goa, has expressed concern over the growing instances of unauthorised sale of ketamine, sildenafil citrate tablets and drugs with psychotropic substances without valid medical prescription in the coastal tourist belt of the State.
Director of Goa FDA Pramod K. Jain, in a public advisory issued here on Thursday, said that the authority is thinking of a cracking down on these irregularities and also the sale of drugs in contravention of Drugs and Cosmetics Rules 1945.
He has warned that any contravention of the rules would be dealt with cancellation or suspension of licence of pharmacies.
Simultaneously, the FDA has decided to issue an advisory against proliferation of unregulated advertisements about drugs that claim to enhance sexual pleasure/drive.
The action is contemplated in response to a grievance raised under the Right to Information Act by the Voluntary Health Association of Goa (VHAG), regarding advertisements of drugs claiming to enhance sexual pleasure appearing in newspapers in violation of the provisions of Indian Drugs and Magic Remedies (Objectionable Advertisement) Act of 1954.
A spokesman of the FDA said they will advise the public not to fall prey to the tall claims made in such advertisements of drugs and to ensure that all drugs were consumed in consultation with medical experts in the respective fields.
The VHAG has requested the FDA to investigate the advertisements of numerous products claiming to increase sexual prowess, which regularly appear in newspapers, Gladstone A. D’Costa, vice-president of VHAG, told The Hindu here on Thursday.
“Many consumers assume that some government agency, such as the FDA, has ruled these products safe before allowing the advertisements to be broadcast and printed. People do not realise, however, that the products are not scientifically proven safe,” said Dr. D’Costa.
The VHAG comprising over 100 doctors, pharmacies, non-government organisations and residents, had undertaken an extensive research which has culminated in sending the communiqué to the FDA, said Dr. D’Costa.